MET and neoplasm: The reduction of miR-9-5p, miR-144, miR-145 and miR-229 leads to tumor progression through the miR-9-5p/POU2F1, miR-144/c-Met, miR-145/ZEB2 and miR-229/VEGFA signaling pathway [14, 28–30].